Cellular Immunotherapy to Target CD3 and HER2 for Oncology is under clinical development by Transtarget and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cellular Immunotherapy to Target CD3 and HER2 for Oncology’s likelihood of approval (LoA) and phase transition for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) took place on 21 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cellular Immunotherapy to Target CD3 and HER2 for Oncology Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cellular Immunotherapy to Target CD3 and HER2 for Oncology overview

Cellular immunotherapy is under development for the treatment of breast cancer, leptomeningeal metastases and metastatic breast cancer. The drug candidate is administered through intraventricular and intravenous routes as infusion. The therapeutic candidate constitutes autologous T cells armed with bi-specific antibody produced by hetero conjugation of anti-CD3 and anti-HER2 monoclonal antibodies. It was also under development for epithelial ovarian cancer, fallopian cancer and peritoneal cancer and metastatic castrate resistant prostate cancer.

Quick View Cellular Immunotherapy to Target CD3 and HER2 for Oncology LOA Data

Report Segments
  • Innovator
Drug Name
  • Cellular Immunotherapy to Target CD3 and HER2 for Oncology
Administration Pathway
  • Intraperitoneal
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Transtarget
  • Originator: Roger Williams Medical Center
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.